Rallybio (NASDAQ:RLYB) Posts Earnings Results, Beats Estimates By $0.02 EPS

Rallybio (NASDAQ:RLYB) posted its quarterly earnings results on Thursday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02, Zacks reports. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.15 million.

Rallybio Price Performance

NASDAQ RLYB opened at $0.63 on Friday. The firm’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.98. The company has a market capitalization of $26.22 million, a price-to-earnings ratio of -0.39 and a beta of -1.45. Rallybio has a 12 month low of $0.62 and a 12 month high of $3.46.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Rallybio in a research report on Wednesday, February 12th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.